Physician profile
Gary Kazlow
NPI 1609840370
$7,366.24
in general payments reported to CMS, 2019-2025
23 companies · $312 in 2025
The $312 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $958 · 2020: $1,025 · 2021: $1,786 · 2022: $1,722 · 2023: $1,000 · 2024: $562 · 2025: $312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,875.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,874.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,796.75 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,319.74 | 2019-2025 | Breztri, Airsupra, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $960.61 | 2019-2023 | Ofev |
| Mylan Specialty L.P. | $926.53 | 2019-2024 | Yupelri |
| Grifols USA, LLC | $680.46 | 2019-2025 | Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $645.32 | 2021-2025 | Dupixent |
| Amgen INC. | $183.66 | 2021-2023 | Tezspire |
| Genentech USA, INC. | $145.38 | 2019-2022 | |
| Genzyme Corporation | $144.16 | 2020-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $96.43 | 2021-2024 | Glassia |
| Teva Pharmaceuticals USA, INC. | $74.88 | 2020-2021 | |
| Viatris Specialty LLC | $67.81 | 2025 | Yupelri |
| Merck Sharp & Dohme LLC | $60.17 | 2019-2021 | |
| Verona Pharma, INC. | $51.94 | 2025 | Ohtuvayre |
| Paratek Pharmaceuticals, INC. | $40.51 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $31.23 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $24.67 | 2019 | |
| Vifor Pharma, INC. | $21.67 | 2024 | Zemaira |
| Horizon Therapeutics Plc | $21.58 | 2020 | |
| Mallinckrodt Hospital Products INC. | $21.48 | 2020 | |
| Circassia INC. | $20.00 | 2019 | |
| United Therapeutics Corporation | $16.10 | 2021 | |
| Insmed, INC. | $15.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Kazlow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.